First Patient(s) Dosed in Ionis Phase 3 ION582 Study

Ionis Pharmaceuticals today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that leads to significant physical and cognitive impairments. 

Read the press release.

Read the letter to the Angelman community.

Watch the recent webinar by Ionis about the ION582 study.